Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Advent Makes Majority Investment in BioDuro, a US-China CRO

publication date: Jan 28, 2019

Advent International, a Boston-based private equity investor, will make a majority investment in BioDuro. BioDuro is a US-China CRO with facilities in San Diego, Beijing and Shanghai. The exact size of the investment was not disclosed. BioDuro was formed in 2005 as a Beijing-based CRO with headquarters in San Diego. In 2009, the China operations were acquired by PPD, the global CRO, for $73 million. It became an independent entity once again in 2015, acquired by its original owners. It then merged with Formex, a San Diego API formulation, development and cGMP manufacturing company. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital